258 related articles for article (PubMed ID: 28741052)
1. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
[TBL] [Abstract][Full Text] [Related]
2. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE
Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
[TBL] [Abstract][Full Text] [Related]
4. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
5. Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.
Sato K; Watanabe R; Hanaoka H; Harada T; Nakajima T; Kim I; Paik CH; Choyke PL; Kobayashi H
Mol Oncol; 2014 May; 8(3):620-32. PubMed ID: 24508062
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy for non-Hodgkin's lymphoma.
Emmanouilides C
Semin Oncol; 2003 Aug; 30(4):531-44. PubMed ID: 12939722
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
9. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
Pagel JM; Orgun N; Hamlin DK; Wilbur DS; Gooley TA; Gopal AK; Park SI; Green DJ; Lin Y; Press OW
Blood; 2009 May; 113(20):4903-13. PubMed ID: 19124831
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
Juweid ME
J Nucl Med; 2002 Nov; 43(11):1507-29. PubMed ID: 12411555
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of radioimmunotherapy to the treatment of lymphoma].
Rizzo-Padoin N
Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Pagel JM; Pantelias A; Hedin N; Wilbur S; Saganic L; Lin Y; Axworthy D; Hamlin DK; Wilbur DS; Gopal AK; Press OW
Cancer Res; 2007 Jun; 67(12):5921-8. PubMed ID: 17575162
[TBL] [Abstract][Full Text] [Related]
13. [Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].
Bello P; Almoguera MI; Pajares M; Olivas C; Lapeña L; Freire JM;
Rev Esp Med Nucl; 2010; 29(1):50-2. PubMed ID: 19963305
[No Abstract] [Full Text] [Related]
14. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
15. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Gopal AK; Press OW; Wilbur SM; Maloney DG; Pagel JM
Blood; 2008 Aug; 112(3):830-5. PubMed ID: 18502830
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
Press OW; Corcoran M; Subbiah K; Hamlin DK; Wilbur DS; Johnson T; Theodore L; Yau E; Mallett R; Meyer DL; Axworthy D
Blood; 2001 Oct; 98(8):2535-43. PubMed ID: 11588052
[TBL] [Abstract][Full Text] [Related]
17. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
[TBL] [Abstract][Full Text] [Related]
18. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
Gokhale AS; Mayadev J; Pohlman B; Macklis RM
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):194-201. PubMed ID: 16111589
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Macklis RM
Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]